Molecular processor

Last updated • 2 min readFrom Wikipedia, The Free Encyclopedia

A molecular processor is a processor that is based on a molecular [1] [2] platform rather than on an inorganic semiconductor in integrated circuit format.

Contents

Current technology

Molecular processors are currently in their infancy and currently only a few exist. At present a basic molecular processor is any biological or chemical system that uses a complementary DNA (cDNA) template to form a long chain amino acid molecule. A key factor that differentiates molecular processors is "the ability to control output" of protein or peptide concentration as a function of time. Simple formation of a molecule becomes the task of a chemical reaction, bioreactor or other polymerization technology. Current molecular processors take advantage of cellular processes to produce amino acid based proteins and peptides. The formation of a molecular processor currently involves integrating cDNA into the genome and should not replicate and re-insert, or be defined as a virus after insertion. Current molecular processors are replication incompetent, non-communicable and cannot be transmitted from cell to cell, animal to animal or human to human. All must have a method to terminate if implanted. The most effective methodology for insertion of cDNA (template with control mechanism) uses capsid technology to insert a payload into the genome. A viable molecular processor is one that dominates cellular function by re-task and or reassignment but does not terminate the cell. It will continuously produce protein or produce on demand and have method to regulate dosage if qualifying as a "drug delivery" molecular processor. Potential applications range from up-regulation of functional CFTR in cystic fibrosis and hemoglobin in sickle cell anemia to angiogenesis in cardiovascular stenosis to account for protein deficiency (used in gene therapy.)

Example

A vector inserted to form a molecular processor is described in part. The objective was to promote angiogenesis, blood vessel formation and improve cardiovasculature. Vascular endothelial growth factor (VEGF) [3] and enhanced green fluorescent protein (EGFP) cDNA was ligated to either side of an internal ribosomal re-entry site (IRES) to produce inline production of both the VEGF and EGFP proteins. After in vitro insertion and quantification [4] of integrating units (IUs), engineered cells produce a bioluminescent marker and a chemotactic growth factor. In this instance, increased fluorescence of EGFP is used to show VEGF production in individual cells with active molecular processors. The production was exponential in nature and regulated through use of an integrating promoter, cell numbers, the number of integrated units (IUs) of molecular processors and or cell numbers. The measure the molecular processors efficacy was performed by FC/FACS to indirectly measure VEGF through fluorescence intensity. Proof of functional molecular processing was quantified by ELISA to show VEGF effect through chemotactic and angiogenesis models. The result involved directed assembly and coordination of endothelial cells for tubule formation [5] by engineered cells on endothelial cells. The research goes on to show implantation and VEGF with dosage capabilities to promote revascularization, validating mechanisms of molecular processor control. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Angiogenesis</span> Blood vessel formation, when new vessels emerge from existing vessels

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels, formed in the earlier stage of vasculogenesis. Angiogenesis continues the growth of the vasculature mainly by processes of sprouting and splitting, but processes such as coalescent angiogenesis, vessel elongation and vessel cooption also play a role. Vasculogenesis is the embryonic formation of endothelial cells from mesoderm cell precursors, and from neovascularization, although discussions are not always precise. The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis is responsible for most, if not all, blood vessel growth during development and in disease.

<span class="mw-page-title-main">Endothelium</span> Layer of cells that line the inner surface of blood vessels

The endothelium is a single layer of squamous endothelial cells that line the interior surface of blood vessels and lymphatic vessels. The endothelium forms an interface between circulating blood or lymph in the lumen and the rest of the vessel wall.

<span class="mw-page-title-main">Platelet-derived growth factor</span> Signaling glycoprotein regulating cell proliferation

Platelet-derived growth factor (PDGF) is one among numerous growth factors that regulate cell growth and division. In particular, PDGF plays a significant role in blood vessel formation, the growth of blood vessels from already-existing blood vessel tissue, mitogenesis, i.e. proliferation, of mesenchymal cells such as fibroblasts, osteoblasts, tenocytes, vascular smooth muscle cells and mesenchymal stem cells as well as chemotaxis, the directed migration, of mesenchymal cells. Platelet-derived growth factor is a dimeric glycoprotein that can be composed of two A subunits (PDGF-AA), two B subunits (PDGF-BB), or one of each (PDGF-AB).

Vascular endothelial growth factor, originally known as vascular permeability factor (VPF), is a signal protein produced by many cells that stimulates the formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis and angiogenesis.

An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet.

<span class="mw-page-title-main">Endostatin</span>

Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. It is reported to serve as an anti-angiogenic agent, similar to angiostatin and thrombospondin.

<span class="mw-page-title-main">Endothelial stem cell</span> Stem cell in bone marrow that gives rise to endothelial cells

Endothelial stem cells (ESCs) are one of three types of stem cells found in bone marrow. They are multipotent, which describes the ability to give rise to many cell types, whereas a pluripotent stem cell can give rise to all types. ESCs have the characteristic properties of a stem cell: self-renewal and differentiation. These parent stem cells, ESCs, give rise to progenitor cells, which are intermediate stem cells that lose potency. Progenitor stem cells are committed to differentiating along a particular cell developmental pathway. ESCs will eventually produce endothelial cells (ECs), which create the thin-walled endothelium that lines the inner surface of blood vessels and lymphatic vessels. The blood vessels include arteries and veins. Endothelial cells can be found throughout the whole vascular system and they also play a vital role in the movement of white blood cells

<span class="mw-page-title-main">Angiopoietin</span> Protein family

Angiopoietin is part of a family of vascular growth factors that play a role in embryonic and postnatal angiogenesis. Angiopoietin signaling most directly corresponds with angiogenesis, the process by which new arteries and veins form from preexisting blood vessels. Angiogenesis proceeds through sprouting, endothelial cell migration, proliferation, and vessel destabilization and stabilization. They are responsible for assembling and disassembling the endothelial lining of blood vessels. Angiopoietin cytokines are involved with controlling microvascular permeability, vasodilation, and vasoconstriction by signaling smooth muscle cells surrounding vessels. There are now four identified angiopoietins: ANGPT1, ANGPT2, ANGPTL3, ANGPT4.

<span class="mw-page-title-main">Thrombospondin 1</span> Protein-coding gene in the species Homo sapiens

Thrombospondin 1, abbreviated as THBS1, is a protein that in humans is encoded by the THBS1 gene.

<span class="mw-page-title-main">VEGF receptor</span> Protein family

VEGF receptors (VEGFRs) are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. Depending on alternative splicing, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR).

<span class="mw-page-title-main">VEGFR1</span> Protein-coding gene in the species Homo sapiens

Vascular endothelial growth factor receptor 1 is a protein that in humans is encoded by the FLT1 gene.

<span class="mw-page-title-main">Thymidine phosphorylase</span> Enzyme

Thymidine phosphorylase is an enzyme that is encoded by the TYMP gene and catalyzes the reaction:

<span class="mw-page-title-main">PEDF</span> Protein-coding gene in the species Homo sapiens

Pigment epithelium-derived factor (PEDF) also known as serpin F1 (SERPINF1), is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. Found in vertebrates, this 50 kDa protein is being researched as a therapeutic candidate for treatment of such conditions as choroidal neovascularization, heart disease, and cancer. In humans, pigment epithelium-derived factor is encoded by the SERPINF1 gene.

<span class="mw-page-title-main">Placental growth factor</span> Protein-coding gene in the species Homo sapiens

Placental growth factor(PlGF) is a protein that in humans is encoded by the PGF gene.

<span class="mw-page-title-main">C-fos-induced growth factor</span> Mammalian protein found in humans

C-fos-induced growth factor (FIGF) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene.

<span class="mw-page-title-main">Vascular endothelial growth factor B</span> Protein-coding gene in the species Homo sapiens

Vascular endothelial growth factor B also known as VEGF-B is a protein that, in humans, is encoded by the VEGF-B gene. VEGF-B is a growth factor that belongs to the vascular endothelial growth factor family, of which VEGF-A is the best-known member.

<span class="mw-page-title-main">Vascular endothelial growth factor A</span> Protein involved in blood vessel growth

Vascular endothelial growth factor A (VEGF-A) is a protein that in humans is encoded by the VEGFA gene.

Angiogenesis is the process of forming new blood vessels from existing blood vessels, formed in vasculogenesis. It is a highly complex process involving extensive interplay between cells, soluble factors, and the extracellular matrix (ECM). Angiogenesis is critical during normal physiological development, but it also occurs in adults during inflammation, wound healing, ischemia, and in pathological conditions such as rheumatoid arthritis, hemangioma, and tumor growth. Proteolysis has been indicated as one of the first and most sustained activities involved in the formation of new blood vessels. Numerous proteases including matrix metalloproteinases (MMPs), a disintegrin and metalloproteinase domain (ADAM), a disintegrin and metalloproteinase domain with throbospondin motifs (ADAMTS), and cysteine and serine proteases are involved in angiogenesis. This article focuses on the important and diverse roles that these proteases play in the regulation of angiogenesis.

<span class="mw-page-title-main">Vasculogenic mimicry</span>

Vasculogenic mimicry (VM) is a strategy used by tumors to ensure sufficient blood supply is brought to its cells through establishing new tumor vascularization. This process is similar to tumor angiogenesis; on the other hand vascular mimicry is unique in that this process occurs independent of endothelial cells. Vasculature is instead developed de novo by cancer cells, which under stress conditions such as hypoxia, express similar properties to stem cells, capable of differentiating to mimic the function of endothelial cells and form vasculature-like structures. The ability of tumors to develop and harness nearby vasculature is considered one of the hallmarks of cancer disease development and is thought to be closely linked to tumor invasion and metastasis. Vascular mimicry has been observed predominantly in aggressive and metastatic cancers and has been associated with negative tumor characteristics such as increased metastasis, increased tissue invasion, and overall poor outcomes for patient survival. Vascular mimicry poses a serious problem for current therapeutic strategies due to its ability to function in the presence of Anti-angiogenic therapeutic agents. In fact, such therapeutics have been found to actually drive VM formation in tumors, causing more aggressive and difficult to treat tumors to develop.

<span class="mw-page-title-main">Endothelial cell anergy</span> Defense mechanism of tumors against immunity

Endothelial cell anergy is a condition during the process of angiogenesis, where endothelial cells, the cells that line the inside of blood vessels, can no longer respond to inflammatory cytokines. These cytokines are necessary to induce the expression of cell adhesion molecules to allow leukocyte infiltration from the blood into the tissue at places of inflammation, such as a tumor. This condition, which protects the tumor from the immune system, is the result of exposure to angiogenic growth factors.

References

  1. ↑ Williams, Kevin Jon (2008). "Molecular processes that handle — and mishandle — dietary lipids". Journal of Clinical Investigation. 118 (10): 3247–59. doi:10.1172/JCI35206. PMC   2556568 . PMID   18830418.
  2. ↑ McBride, C; Gaupp, D; Phinney, DG (2003). "Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR". Cytotherapy. 5 (1): 7–18. doi:10.1080/14653240310000038. PMID   12745583.
  3. ↑ Leung, D.; Cachianes, G; Kuang, W.; Goeddel, D.; Ferrara, N (1989). "Vascular endothelial growth factor is a secreted angiogenic mitogen". Science. 246 (4935): 1306–9. Bibcode:1989Sci...246.1306L. doi:10.1126/science.2479986. PMID   2479986.
  4. ↑ Leutenegger, C; Klein, D; Hofmann-Lehmann, R; Mislin, C; Hummel, U; Böni, J; Boretti, F; Guenzburg, WH; Lutz, H (1999). "Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system". Journal of Virological Methods. 78 (1–2): 105–16. doi:10.1016/S0166-0934(98)00166-9. PMID   10204701.
  5. ↑ Vernon, RB; Sage, EH (1999). "A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices". Microvascular Research. 57 (2): 118–33. doi:10.1006/mvre.1998.2122. PMID   10049660.
  6. ↑ Russell Auger, PhD., Mesenchymal stromal cells as angiogenic cellular vectors for revascularizing the heart., 08.2006: PhD Thesis Publication available at Tulane University Library and through UMI Copyright 2006–2007.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.